WUXI
WXIDrugs in Pipeline
15
Phase 3 Programs
10
Upcoming Catalysts
4
Next Catalyst
Jul 31, 2026
17wMarket Overview
Stock performance and key metrics
4 upcoming, 1 past
5 mg BGM0504 injection
Overweight or Obesity
Guideline-directed medical therapy (GDMT) for heart failure
Pulmonary Hypertension
Mesenchymal Stem Cells
Knee Osteoarthritis
CU-20101 treatment for Moderate to Severe Glabellar Striae
Glabellar Frown Lines
CU-40102 Spray
AGA
Lidocaine tetracaine cream
Analgesia
Semaglutide
Type 2 Diabetes (T2DM)
BGM0504
Obesity
Drug: 5 mg BGM0504 Administered SC
Type 2 Diabetes Mellitus (T2DM)
Drug: : 10 mg BGM0504 Administered SC
Type 2 Diabetes Mellitus (T2DM)
D3S-001
KRAS P.G12C
CU-20401
Safety
Subcutaneous injection of CU-20401
Efficacy and Safety
BGM0504 Administered SC
Type 2 Diabetes
D3S-002
Advanced Solid Tumors With MAPK Pathway Mutations
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
5 mg BGM0504 injection | Phase 3 | Overweight or Obesity | - | - |
Guideline-directed medical therapy (GDMT) for heart failure | Phase 3 | Pulmonary Hypertension | - | - |
Mesenchymal Stem Cells | Phase 3 | Knee Osteoarthritis | - | - |
CU-20101 treatment for Moderate to Severe Glabellar Striae | Phase 3 | Glabellar Frown Lines | - | - |
CU-40102 Spray | Phase 3 | AGA | - | - |
Lidocaine tetracaine cream | Phase 3 | Analgesia | - | - |
Semaglutide | Phase 3 | Type 2 Diabetes (T2DM) | - | - |
BGM0504 | Phase 3 | Obesity | - | - |
Drug: 5 mg BGM0504 Administered SC | Phase 3 | Type 2 Diabetes Mellitus (T2DM) | - | - |
Drug: : 10 mg BGM0504 Administered SC | Phase 3 | Type 2 Diabetes Mellitus (T2DM) | - | - |
D3S-001 | Phase 2 | KRAS P.G12C | - | - |
CU-20401 | Phase 2 | Safety | - | - |
Subcutaneous injection of CU-20401 | Phase 2 | Efficacy and Safety | - | - |
BGM0504 Administered SC | Phase 2 | Type 2 Diabetes | - | - |
D3S-002 | Phase 2 | Advanced Solid Tumors With MAPK Pathway Mutations | - | - |